Get the Weekly Intelligence Brief — top committee picks every Sunday.

INGR vs UTI

Ingredion vs Universal Technical Institute, Inc. — AI-powered side-by-side comparison
INGR
Ingredion
62
Buy
VS
UTI
Universal Technical Institute, Inc.
53
Watch
MetricINGRUTI
AI Score 62 53
Price $104.70 $25.56
P/E Ratio 11.25× 40.60×
ROE 16.8% 19.2%
Revenue Growth YoY
Gross Margin 23.7% 61.5%
Debt / Equity 0.39× 1.04×
Dividend Yield 3.1% 0.0%
RSI (14) 57.8 20.6
Beta 0.606 1.236
Expected Upside +1.6%

AI Committee View

Current Innellis committee reasoning for INGR versus UTI.
INGR leads by 9 points.

INGR scores 62/100 (Buy) versus UTI at 53/100 (Watch).

INGR Committee View
60% agreement
5 analysts

The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is revenue declining -1.4% yoy -- this is not a growth story right now. The committee is constructive but not yet at full conviction.

Bull Case
  • P/E of 11.1 is inexpensive for the broad market — Value
  • Dividend yield of 3.2% pays you to wait — Value
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
  • Revenue declining -1.4% YoY -- this is not a growth story right now — Growth
  • EPS declining -10.3% YoY despite any revenue growth — Growth
UTI Committee View
67% agreement
6 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Technical Analyst remains cautious — rsi at 21 is in oversold territory (could mean either capitulation or a bounce setup). This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • Low leverage (debt-to-equity 0.27) -- balance sheet can absorb a shock — Risk
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • P/E of 37.4 is moderate-to-rich — Value
  • Price-to-book of 5.4x prices in significant intangible value — Value
  • EPS declining -25.9% YoY despite any revenue growth — Growth
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
INGR Full Analysis UTI Full Analysis